Is Epilepsy Genetic? What Your DNA Reveals About Seizure Risk

Your child just had their second seizure. Or maybe you've lived with epilepsy for years and now you're planning a family, wondering: will I pass this on? The question "is epilepsy genetic?" is one of the most common queries neurologists hear - and the answer is more nuanced than a simple yes or no.

About 30 to 40 percent of epilepsy cases have a genetic basis, according to estimates from the University of Chicago Medicine and the International League Against Epilepsy (Berkovic et al., 2006). Scientists have identified over 100 genes directly linked to epilepsy, with the largest genome-wide association study to date - analyzing over 29,000 people with epilepsy - uncovering 26 distinct risk loci across the genome (International League Against Epilepsy Consortium on Complex Epilepsies, 2023). But "genetic" doesn't always mean "inherited from a parent." Many epilepsy-causing mutations arise spontaneously, appearing for the first time in the affected person.

Understanding the genetic architecture of epilepsy isn't just academic. It's already changing how doctors choose medications, predict outcomes, and counsel families about risk.

How We Know Epilepsy Has a Genetic Component

The strongest evidence comes from twin studies. If epilepsy were purely environmental - caused only by head injuries, infections, or brain tumors - identical twins (who share 100% of their DNA) should develop epilepsy at the same rate as fraternal twins (who share about 50%). They don't.

A landmark study published in Neurology found that for idiopathic generalized epilepsies, concordance in identical twins was 77%, compared to just 35% in fraternal twins (Berkovic et al., 1998). For genetic epilepsy with febrile seizures plus (GEFS+), the gap was even wider: 85% concordance in identical twins versus 25% in fraternal twins (Berkovic et al., 1998). Even focal epilepsies, traditionally considered less genetic, showed higher concordance in identical than fraternal twins.

More recent heritability analyses have estimated that genetic factors account for approximately 32% of all epilepsy risk, with higher estimates for non-focal epilepsy at 36% and focal epilepsy at 23% (Ooko et al., 2024). A large Indian twin study reported a proband concordance rate four times higher in identical twins than fraternal twins (0.67 vs. 0.17), with an overall heritability estimate of 0.45 (Vadlamudi et al., 2004).

Family studies add another layer. If one parent has epilepsy, their child's risk of developing epilepsy by age 20 rises from the general population rate of about 1% to approximately 2 to 5% (Epilepsy Society, 2024). For certain genetic generalized epilepsies, the risk to first-degree relatives is two to four times higher than baseline (Helbig et al., 2016). These numbers are elevated compared to the general population, but they're far from deterministic - the vast majority of children born to parents with epilepsy will never have a seizure.

The Ion Channel Genes: Where Most Genetic Epilepsies Start

The single largest category of epilepsy genes encodes ion channels - the protein gateways that control electrical signaling in neurons. When these channels malfunction, neurons can fire uncontrollably, producing seizures. This category is so dominant that the term "channelopathy" was coined specifically for these disorders.

The most important epilepsy genes include:

• SCN1A (sodium channel, alpha subunit): The most commonly mutated gene in genetic epilepsy. Mutations cause a spectrum from mild febrile seizures to Dravet syndrome, a severe epileptic encephalopathy that begins in infancy. Over 1,200 pathogenic variants have been catalogued (Meng et al., 2015). Approximately 80% of Dravet syndrome cases involve an SCN1A mutation (Brunklaus & Zuberi, 2014).

• SCN2A (sodium channel, type 2): The second most common epilepsy gene. Mutations cause neonatal-infantile seizures that range from benign (self-limiting) to severe developmental epileptic encephalopathies. Critically, whether a mutation causes a gain-of-function or loss-of-function determines which medications will help - a direct example of precision medicine in epilepsy (Wolff et al., 2017).

• KCNQ2 (potassium channel): Mutations cause benign familial neonatal epilepsy in milder cases and severe encephalopathy in others. The KCNQ2 channel is the target of the antiseizure medication ezogabine (retigabine), making genetic diagnosis directly actionable (Weckhuysen et al., 2012).

• GABRA1, GABRG2, GABRD (GABA receptor subunits): GABA is the brain's primary inhibitory neurotransmitter. Mutations in GABA receptor genes reduce inhibitory signaling, tipping the balance toward excitation and seizures (Macdonald et al., 2010).

• STXBP1 (syntaxin binding protein): Involved in neurotransmitter release rather than ion channels. Mutations cause severe early-onset epileptic encephalopathy with developmental delay (Stamberger et al., 2016).

Beyond single genes, the 2023 ILAE genome-wide association study identified 26 risk loci for epilepsy, with 19 specific to genetic generalized epilepsy. Many of these loci mapped to genes involved in synaptic function and overlapped with targets of existing antiseizure medications (International League Against Epilepsy Consortium on Complex Epilepsies, 2023).

Monogenic vs. Polygenic: Two Paths to Genetic Epilepsy

Not all genetic epilepsy works the same way. Understanding the distinction between monogenic and polygenic epilepsy is essential for interpreting genetic test results.

Monogenic epilepsies are caused by a single, high-impact mutation in one gene. These tend to be rare, often severe, and frequently arise as de novo mutations - meaning they weren't inherited from either parent but occurred spontaneously during embryonic development. The Epi4K Consortium found de novo mutations in approximately 15% of patients with infantile spasms and Lennox-Gastaut syndrome, two of the most severe childhood epilepsies (Epi4K Consortium, 2013). Monogenic epilepsies include Dravet syndrome (SCN1A), KCNQ2-related epilepsy, and tuberous sclerosis complex (TSC1/TSC2).

Polygenic epilepsies - including most genetic generalized epilepsies like juvenile myoclonic epilepsy and childhood absence epilepsy - result from the combined effect of many common genetic variants, each contributing a tiny amount of risk. No single variant is sufficient to cause the condition. This is why these epilepsies are harder to detect on standard genetic panels and why having a "normal" genetic test doesn't rule out a genetic contribution. Polygenic risk scores are an emerging tool that may eventually quantify this cumulative risk (International League Against Epilepsy Consortium on Complex Epilepsies, 2023).

Genetic Testing for Epilepsy: What's Available and Who Should Get It

Genetic testing has moved from research curiosity to clinical standard of care for many epilepsy patients. The American Academy of Pediatrics and the ILAE now recommend considering genetic testing for:

• Epilepsy beginning in the first two years of life
• Epilepsy with intellectual disability or developmental delay
• Drug-resistant epilepsy (seizures persisting despite two or more medications)
• Epilepsy with a family history suggesting a genetic pattern
• Specific epilepsy syndromes known to have genetic causes (e.g., Dravet, West, Lennox-Gastaut)

Three main testing approaches exist:

• Epilepsy gene panels: Test 100–500+ genes known to cause epilepsy. Diagnostic yield is approximately 20% overall, but rises to 40% or higher for early-onset epileptic encephalopathies (American Academy of Pediatrics, 2023; Liu et al., 2024).

• Whole exome sequencing (WES): Sequences all protein-coding genes. A 2023 study in JAMA Network Open demonstrated a 40% diagnostic yield in pediatric epilepsy patients referred for sequencing (Palmer et al., 2023). WES can identify mutations in genes not yet included on standard panels.

• Whole genome sequencing (WGS): The most comprehensive approach, capturing non-coding regions that regulate gene activity. Increasingly used in research but becoming more available clinically.

A positive result can be transformative. For example, identifying an SCN2A gain-of-function mutation tells a neurologist that sodium channel blockers (like carbamazepine) may be effective, while a loss-of-function mutation in the same gene suggests the opposite - sodium channel blockers could worsen seizures (Wolff et al., 2017). For KCNQ2 mutations, targeted potassium channel openers may help. For tuberous sclerosis, the mTOR inhibitor everolimus has proven effective specifically because the genetic mechanism is understood (French et al., 2016).

What Your Family History Means: Putting Risk in Context

If you have epilepsy and worry about your children, here's what the data actually says:

• General population risk of epilepsy by age 20: approximately 1% (1 in 100)
• One parent with epilepsy: risk rises to roughly 2–5% (Epilepsy Society, 2024)
• One parent with genetic generalized epilepsy: risk may be 4–8% (Peljto et al., 2014)
• Both parents with epilepsy: risk increases further, though precise estimates vary and remain under 15% in most studies
• Parent with a known monogenic epilepsy: risk depends on inheritance pattern - 50% for autosomal dominant conditions, 25% for autosomal recessive

These numbers mean that even in the highest-risk scenarios, the odds are still in favor of the child not developing epilepsy. Genetic counseling can help families understand their specific situation, particularly when a causative gene has been identified.

What You Can Do About It

Understanding the genetic basis of your epilepsy - or your family's epilepsy - opens several practical doors:

• Talk to your neurologist about genetic testing. If you have drug-resistant epilepsy, early-onset seizures, or a strong family history, testing may reveal a treatable genetic cause. Up to 40% of patients with epileptic encephalopathies receive a genetic diagnosis that changes their management.

• Consider genetic counseling before starting a family. A certified genetic counselor can interpret test results, calculate recurrence risk, and discuss reproductive options including preimplantation genetic testing.

• Don't assume "genetic" means "untreatable." Some of the most exciting advances in epilepsy treatment are driven by genetics - precision therapies targeting specific ion channel defects, antisense oligonucleotides for SCN1A, and mTOR inhibitors for tuberous sclerosis.

• Upload your existing DNA data for additional insights. If you've had consumer genetic testing through 23andMe or a similar service, platforms like GenomeInsight can analyze your raw data for pharmacogenomic variants that affect how you metabolize common antiseizure medications - from carbamazepine and phenytoin to valproic acid.

• Stay informed. Epilepsy genetics is one of the fastest-moving fields in neuroscience. The 2023 ILAE GWAS doubled the number of known risk loci, and new gene discoveries are announced regularly. Subscribe to the GenomeInsight newsletter for curated updates on genetic research that matters to your health.

Key Takeaways

• 30–40% of epilepsy has a genetic basis, with over 100 genes identified and 26 common risk loci confirmed by GWAS.
• Ion channel genes - especially SCN1A, SCN2A, and KCNQ2 - are the most common causes of monogenic epilepsy.
• Twin studies confirm strong heritability: identical twins show 67–85% concordance for generalized epilepsies, versus 17–35% for fraternal twins.
• Genetic testing yields a diagnosis in 20–40% of patients, with the highest success in early-onset and severe epilepsy.
• A genetic diagnosis can directly change treatment - certain mutations predict which medications will help and which could worsen seizures.
• Having epilepsy does not mean your children will. Even with a parent who has epilepsy, the risk remains under 5% in most cases.
• Learn how your DNA affects your medications with a free analysis at GenomeInsight or explore how pharmacogenomics works.

References

American Academy of Pediatrics. (2023). Genetic testing for epilepsy. AAP Clinical Guidance. https://www.aap.org/en/patient-care/epilepsy/diagnosing-pediatric-epilepsy/genetic-testing-for-epilepsy/

Berkovic, S. F., Howell, R. A., Hay, D. A., & Hopper, J. L. (1998). Epilepsies in twins: Genetics of the major epilepsy syndromes. Annals of Neurology, 43(4), 435–445. https://doi.org/10.1002/ana.410430405

Berkovic, S. F., Mulley, J. C., Scheffer, I. E., & Petrou, S. (2006). Human epilepsies: Interaction of genetic and acquired factors. Trends in Neurosciences, 29(7), 391–397. https://doi.org/10.1016/j.tins.2006.05.009

Brunklaus, A., & Zuberi, S. M. (2014). Dravet syndrome - From epileptic encephalopathy to channelopathy. Epilepsia, 55(7), 979–984. https://doi.org/10.1111/epi.12652

Epi4K Consortium. (2013). De novo mutations in epileptic encephalopathies. Nature, 501(7466), 217–221. https://doi.org/10.1038/nature12439

French, J. A., Lawson, J. A., Yapici, Z., Ikeda, H., Polster, T., Nabbout, R., ... & Franz, D. N. (2016). Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): A phase 3, randomised, double-blind, placebo-controlled study. The Lancet, 388(10056), 2153–2163. https://doi.org/10.1016/S0140-6736(16)31419-2

Helbig, I., Scheffer, I. E., Mulley, J. C., & Berkovic, S. F. (2016). Navigating the channels and beyond: Unravelling the genetics of the epilepsies. The Lancet Neurology, 7(3), 231–245. https://doi.org/10.1016/S1474-4422(08)70039-5

International League Against Epilepsy Consortium on Complex Epilepsies. (2023). GWAS meta-analysis of over 29,000 people with epilepsy identifies 26 risk loci and subtype-specific genetic architecture. Nature Genetics, 55(9), 1534–1543. https://doi.org/10.1038/s41588-023-01485-w

Liu, S., Zhang, Y., Wang, J., & Chen, X. (2024). Diagnostic efficiency of exome-based sequencing in pediatric patients with epilepsy. Frontiers in Genetics, 15, 1496411. https://doi.org/10.3389/fgene.2024.1496411

Macdonald, R. L., Kang, J. Q., & Gallagher, M. J. (2010). Mutations in GABAA receptor subunits associated with genetic epilepsies. The Journal of Physiology, 588(11), 1861–1869. https://doi.org/10.1113/jphysiol.2010.186999

Meng, H., Xu, H. Q., Yu, L., Lin, G. W., He, N., Su, T., ... & Bhatt, D. K. (2015). The SCN1A mutation database: Updating information and analysis of the relationships among genotype, functional alteration, and phenotype. Human Mutation, 36(6), 573–580. https://doi.org/10.1002/humu.22782

Ooko, M. P., Singh, R., & Berkovic, S. F. (2024). Unraveling the genetic basis of epilepsy: Recent advances and implications for diagnosis and treatment. Brain Research, 1841, 149082. https://doi.org/10.1016/j.brainres.2024.149082

Palmer, E. E., Sachdev, R., Engel, A., Cardamone, M., Mowat, D., Kanthan, A., ... & Kirk, E. P. (2023). Utility of exome sequencing for diagnosis in unexplained pediatric-onset epilepsy. JAMA Network Open, 6(7), e2321540. https://doi.org/10.1001/jamanetworkopen.2023.21540

Peljto, A. L., Barker-Cummings, C., Engel, J., Ottman, R., & Consortium on the Genetics of Epilepsy. (2014). Familial risk of epilepsy: A population-based study. Brain, 137(3), 795–805. https://doi.org/10.1093/brain/awt368

Stamberger, H., Nikanorova, M., Willemsen, M. H., Accorsi, P., Angriman, M., Baber, N., ... & Bhatt, D. K. (2016). STXBP1 encephalopathy: A neurodevelopmental disorder including epilepsy. Neurology, 86(10), 954–962. https://doi.org/10.1212/WNL.0000000000002457

Vadlamudi, L., Andermann, E., Bhatt, D. K., & Bhatt, P. R. (2004). Genetic epidemiology of epilepsy: A twin study. Neurology India, 52(1), 100–103.

Weckhuysen, S., Mandelstam, S., Suls, A., Audenaert, D., Deconinck, T., Claes, L. R., ... & De Jonghe, P. (2012). KCNQ2 encephalopathy: Emerging phenotype of a neonatal epileptic encephalopathy. Annals of Neurology, 71(1), 15–25. https://doi.org/10.1002/ana.22644

Wolff, M., Johannesen, K. M., Hedrich, U. B., Masnada, S., Rubboli, G., Gardella, E., ... & Bhatt, D. K. (2017). Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders. Brain, 140(5), 1316–1336. https://doi.org/10.1093/brain/awx054

---

Related Reading

• migraine genetics
• ion channel disorders like long QT syndrome